<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04421456</url>
  </required_header>
  <id_info>
    <org_study_id>GWAP19030</org_study_id>
    <secondary_id>2019-003369-16</secondary_id>
    <nct_id>NCT04421456</nct_id>
  </id_info>
  <brief_title>Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment</brief_title>
  <official_title>A Randomized, Double-blind, Parallel-group Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GW Research Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GW Research Ltd</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the efficacy, safety, and tolerability of GWP42003-P
      versus placebo in participants with schizophrenia experiencing inadequate response to ongoing
      antipsychotic treatment.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2020</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean change from Baseline in the Structured Clinical Interview Positive and Negative Symptoms Scale (SCI-PANSS) total (PANSS-T) score</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from Baseline in the Clinical Global Impression of Severity (CGI-S) score</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical Global Impression of Improvement (CGI-I) score</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from Baseline in the PANSS positive subscale (PANSS-P) score</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from Baseline in the PANSS negative subscale (PANSS-N) score</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from Baseline in the PANSS general subscale (PANSS-G) score</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in body weight</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in body mass index (BMI)</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in waist circumference</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in blood pressure</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in heart rate</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in respiratory rate</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in temperature</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events (AEs) and adverse drug reactions (ADRs)</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the Extrapyramidal Symptom Rating Scale (ESRS) score, as an assessment of extrapyramidal symptoms</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant clinical laboratory test results</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with clinically significant 12 lead electrocardiogram (ECG) parameter values</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the Calgary Depression Scale for Schizophrenia (CDSS) score</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the Columbia Suicide Severity Rating Scale (C-SSRS) score, as an assessment of suicidality</measure>
    <time_frame>from Baseline up to 14 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>GWP42003-P 300 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GWP42003-P 300 milligrams (mg) per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GWP42003-P 1000 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GWP42003-P 1000 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GWP42003-P</intervention_name>
    <description>oral solution containing 100 milligrams per milliliter (mg/mL) cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol (10% v/v), with sweetener (sucralose), and strawberry flavoring</description>
    <arm_group_label>GWP42003-P 1000 mg</arm_group_label>
    <arm_group_label>GWP42003-P 300 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral solution containing the excipients sesame oil and anhydrous ethanol, with added β-carotene, sweetener (sucralose), and strawberry flavoring</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female 18 to 50 years of age at the time of signing the Informed Consent Form
             (ICF)

          -  Willing and able to give informed consent for participation in the trial

          -  Diagnostic and Statistical Manual of Mental Disorders (DSM-5) diagnosis of
             schizophrenia, confirmed by the Mini International Neuropsychiatric Interview (MINI)

          -  Clinically stable outpatient

          -  PANSS-T score of ≥ 60 and &lt; 110 at screening and baseline visits

          -  Score of ≥ 4 for at least 2 of the following PANSS items: delusions (P1), conceptual
             disorganization (P2), hallucinatory behavior (P3), suspiciousness (P6), or unusual
             thought content (G9) at screening and baseline visits

          -  Score ≥ 4 (at least moderately ill) on the Clinical Global Impression of Severity
             (CGI-S) at screening and baseline visits.

          -  Undergoing treatment with at least 1 antipsychotic medication with no change in
             dosing, supported by documentation, for at least 8 weeks prior to screening and no
             change in antipsychotic medication dosing planned throughout the trial

          -  Documented response (at least partially) to treatment with current antipsychotic
             medications (e.g., treatment of recent exacerbation of psychotic symptoms)

          -  On a stable dose if taking concomitant psychotropic medications and within allowed
             limits, including antidepressants, anxiolytics, anticholinergics and/or antiepileptics
             for at least 8 weeks prior to screening. Valproic acid or any prescribed valproate
             product (valproate semisodium or valproate sodium) is disallowed within 4 weeks (i.e.,
             more than 5 half lives) prior to the baseline visit.

        Exclusion Criteria:

        Diagnosis and Psychiatric History

          -  Recent (within the last 6 months) diagnosis of panic disorder, depressive episode, or
             other comorbid psychiatric conditions based on the MINI (or DSM-5) or has PANSS item
             G6 score of ≥ 5 (depression)

          -  Any psychiatric disorder that may interfere with the conduct of this trial, including
             but not limited to attention deficit hyperactivity disorder, pervasive developmental
             disorder, intellectual disability, personality disorder that might interfere with
             compliance or increase suicidal risk, manic or hypomanic episode, or any other
             psychotic disorder, as defined in the DSM-5

          -  Any history of suicidal behavior or any suicidal ideation of type 4 or 5 on the adult
             C-SSRS or within 1 month prior to screening

        Treatment History

          -  Treatment-resistant schizophrenia as judged by the treating physician, as defined by
             having previously failed &gt; 2 therapeutic antipsychotic trial medications i.e.:

               1. At least 6 weeks duration of treatment at therapeutic doses;

               2. Two different classes of antipsychotic medications;

               3. Or required clozapine therapy due to non-response to antipsychotic therapy within
                  the previous 5 years.

          -  Based on the investigator assessment, current antipsychotic medication blood levels
             are below the therapeutic range (only applicable when therapeutic drug monitoring is
             available for the antipsychotic[s] prescribed for the participant)

        Past and Current Medical History

          -  History of moderate or severe head trauma (for example, loss of consciousness for more
             than 15 minutes) or other neurological disorders (including epilepsy),
             neurodegenerative disorder (Alzheimer's disease, Parkinson's disease, multiple
             sclerosis, Huntington's disease, etc.) or systemic medical diseases that are, in the
             opinion of the investigator, likely to interfere with the conduct of the trial or
             confound the trial assessments

          -  Tardive dyskinesia (TD) that is moderate to severe (i.e., a score of &gt; 21 on the
             dyskinesia subscale of the Extrapyramidal Symptom Rating Scale [ESRS]) or requires
             treatment

          -  Any other significant disease, disorder, pending court proceedings or social
             circumstances which, in the opinion of the investigator, may either put the
             participant at risk because of participation in the trial, may influence the result of
             the trial, or may affect the participant's ability to take part in the trial

        Other

          -  Any known or suspected hypersensitivity to cannabinoids or any of the excipients of
             the investigational medicinal product, such as sesame seed oil

          -  One or more laboratory values outside the normal range, based on the blood or urine
             samples taken at the screening visit, that are considered by the investigator to be
             clinically significant; or impaired hepatic function at screening, defined as serum
             alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &gt; 2 × upper limit
             of normal (ULN) or total bilirubin (TBL) &gt; 1.5 × ULN or international normalized ratio
             (INR) &gt; 1.2 (TBL ULN parameter not applicable for participants diagnosed with
             Gilbert's disease)

          -  Currently using or within 3 months of screening has used cannabidiol (CBD) oil or
             purified CBD preparations and is unwilling to abstain for the duration of the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Medical Information</last_name>
    <phone>+44 (0) 1223 266 800</phone>
    <email>medinfo@gwpharm.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Medical Information</last_name>
    <phone>(833) 424-6724</phone>
    <email>medinfo@greenwichbiosciences.com</email>
  </overall_contact_backup>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 27, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 9, 2020</study_first_posted>
  <last_update_submitted>June 4, 2020</last_update_submitted>
  <last_update_submitted_qc>June 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GWP42003-P</keyword>
  <keyword>adjunctive therapy</keyword>
  <keyword>inadequate response to ongoing antipsychotic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

